Yangli Medicine hat eine Finanzierung in Serie B im Wert von Hunderten von Millionen Yuan abgeschlossen, die exklusiv von Qiming Venture Partners investiert wurde.
Recently, the innovative drug development company Zhejiang Yangli Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Yangli Pharmaceutical") announced the completion of a billion - level Series B financing. This round of financing was exclusively invested by Qiming Venture Partners. The existing shareholders of the company also include Taifu Capital, Hangzhou State - owned Assets, and Runzhang Venture Capital. The funds from this financing round will be used for the clinical advancement of several of the company's products.
Yangli Pharmaceutical was founded in 2021. Based in Hangzhou, the company is located in China and adheres to international standards. The company focuses on the development of Category 1 innovative drugs with global intellectual property rights, which are first - in - class or best - in - class. It focuses on therapies for cancer and chronic diseases, and several products are already in Phase I and Phase II of clinical trials.
Yangli Pharmaceutical has brought together top international experts in drug innovation and management. The core founding team of the company has studied at Tsinghua University, the University of California, Los Angeles, the State University of New York, the West China School of Medicine of Sichuan University (formerly West China Medical University), and the University of Hong Kong.
Dr. Sha Wei, the founder and president of Yangli Pharmaceutical, has rich industry experience. Before founding Yangli Pharmaceutical, Dr. Sha Wei was the general director of the Taifu Institute of Taifu Pharmaceutical Group, a founding shareholder of Yangli Pharmaceutical. Her experiences cover the entire process from drug development to market launch, which has laid a solid foundation for the company's development and industrialization of innovative drugs.
Dr. Ding Zhaozhong, the co - founder and chairman of Yangli Pharmaceutical, has more than 30 years of experience in drug development and management, bringing valuable development knowledge to Yangli Pharmaceutical.
Dr. Fang Dong, the chief scientist of Yangli Pharmaceutical, brings over 20 years of experience in drug discovery and development. Dr. Fang Dong has participated in the development of several marketed new cancer drugs such as Lisaftoclax, Olverembatinib, Iruplinalkib, and Glasdegib and has promoted the applications for dozens of new drug clinical trials in China and the United States. He has published more than 40 peer - reviewed scientific articles and holds more than 20 patents.
The strong team of professionals provides the core driving force for the company's development of innovative drugs. Currently, Yangli Pharmaceutical has made significant progress in the development of several innovative drugs covering the fields of hypertension and various solid tumors. The products in the clinical phase include the highly selective aldosterone synthase inhibitor VB19055 and the small - molecule targeting drugs TFX05, TFX06, and VB15. The pre - clinical pipelines for small molecules and small nucleic acids cover diseases such as cancer, hypertension, hyperlipidemia, and diabetes.
Yangli Pharmaceutical has received a series of awards due to its outstanding performance in the field of innovative drugs, including being recognized as a national high - tech enterprise, a national knowledge - based small and medium - sized enterprise, an innovative small and medium - sized enterprise in Zhejiang Province, an enterprise for talent leadership in 2024, and the 9th "Dayun Talents" innovation and entrepreneurship project.
Dr. Ding Zhaozhong, the co - founder and chairman of Yangli Pharmaceutical, said: "I would like to thank all investment institutions for their continuous trust and support for Yangli Pharmaceutical. Since its establishment, the company has always developed differentiated products from the ground up around unmet clinical needs and follows the R & D concept of 'In China, For Global'. With its advantageous platforms for small molecules and small nucleic acids, the company has built pipelines for cancer and chronic diseases. The successful completion of this financing round shows the high recognition of investors for the clinical competitiveness and market potential of our pipelines. This financing paves the way for the registration - oriented clinical phase of our cancer drug product line and the clinical validation of our products for chronic diseases. It marks Yangli Pharmaceutical's entry into a phase of rapid growth and brings us one step closer to the commercialization of innovative drugs. Our goal and mission are to create value for investors and bring health to patients."
Dr. Chen Kan, a partner at Qiming Venture Partners and in charge of the medical innovation industry, said: "Yangli Pharmaceutical has created differentiated innovations from the ground up by using forward - looking target selection and an efficient platform for compound optimization and has developed a series of candidate molecules with high activity, high specificity, and excellent safety. We are convinced that these molecules will quickly move from the pipeline to the market under the strength of the company's clinical development capabilities and will unleash their enormous clinical and market potential to ultimately meet the urgent clinical needs of patients worldwide."
This article is from the WeChat account "Qiming Venture Partners" and was published by 36 Kr with permission.